Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of August 2019, with the report dated August 7, 2019. The filing announces a strategic transaction involving Evogene's agriculture biologicals subsidiary, Lavie Bio Ltd.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for Evogene Ltd. or Lavie Bio Ltd. for this period.
Key transaction values disclosed include:
- Equity Investment: $10 million cash investment by Corteva Inc.
- Asset Exchange: Exchange of all shares of Corteva's wholly owned subsidiary, Taxon Biosciences, for Lavie Bio shares.
- Post-Transaction Ownership: Corteva will hold 28% of Lavie Bio's equity; Evogene will retain 72%.
Material Changes
The primary material change is the agreement with Corteva Inc. to invest in and commercialize Lavie Bio's products. This includes:
- Acquisition of a 28% equity stake in Lavie Bio by Corteva.
- Transfer of Taxon Biosciences assets from Corteva to Lavie Bio.
- Establishment of commercial arrangements for Corteva to commercialize Lavie Bio's products, primarily in corn and soybean markets.
Guidance, Outlook, and Risks
Outlook: Consummation of the transaction is expected by the end of the third quarter of 2019.
Commercial Strategy: The partnership aims to leverage Corteva's distribution capabilities for Lavie Bio's biological products in major crop sectors.
Risks and Contingencies: The filing does not explicitly detail risks or contingencies beyond the standard expectation that the transaction must be consummated to realize the outlined benefits.
Investor Verification Checklist
- Verify the closing date of the transaction to confirm it occurs by the end of Q3 2019.
- Review the specific terms of the commercial arrangement regarding revenue sharing or royalties for corn and soybean products.
- Assess the valuation of Taxon Biosciences relative to the $10 million cash investment to understand the total deal value.
- Monitor future filings for the impact of this transaction on Evogene's consolidated financial statements.